AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-1.45%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$635M
AUM Growth
+$635M
(+3.2%)
Cap. Flow
+$13M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
39.19%
Holding
115
New
23
Increased
29
Reduced
18
Closed
15
Top Buys
| 1 |
Alkermes
ALKS
|
$13.9M |
| 2 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$11.9M |
| 3 |
Apogee Therapeutics
APGE
|
$9.61M |
| 4 |
Arcellx
ACLX
|
$8.83M |
| 5 |
Insmed
INSM
|
$8.38M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$9.7M |
| 2 |
Absci
ABSI
|
$5.82M |
| 3 |
Cytokinetics
CYTK
|
$5.61M |
| 4 |
Fulcrum Therapeutics
FULC
|
$5.2M |
| 5 |
Axsome Therapeutics
AXSM
|
$4.81M |
Sector Composition
| 1 | Healthcare | 89.38% |
| 2 | Financials | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Protagonist Therapeutics
PTGX
$3.62B
| – | – |
-100,000
| Closed | -$2.89M |
|
102
Regenxbio
RGNX
$498M
| – | – |
-110,000
| Closed | -$2.32M |
|
103
Sana Biotechnology
SANA
$759M
| – | – |
0
| – | – |
|
104
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
105
Terns Pharmaceuticals
TERN
$651M
| – | – |
-450,000
| Closed | -$2.95M |
|
106
Tourmaline Bio
TRML
$645M
| – | – |
-50,000
| Closed | -$1.15M |
|
107
Travere Therapeutics
TVTX
$1.75B
| – | – |
-125,000
| Closed | -$964K |
|
108
Twist Bioscience
TWST
$1.57B
| – | – |
0
| – | – |
|
109
Viking Therapeutics
VKTX
$3.02B
| – | – |
-50,000
| Closed | -$4.1M |
|
|
ITCI
110
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-50,000
| Closed | -$3.46M |
|